文献速递胸部肿瘤放疗姑息放疗与转移瘤

间质性肺疾病患者接受姑息性放疗伴或不伴肺部照射的影响

Impact of palliative radiotherapy with or without lung irradiation in patients with interstitial lung disease.
PubMed 文献 · Radiother Oncol · 2023-03-22

回顾性分析103例间质性肺疾病患者接受姑息性放疗,中位影像随访88天、生存随访144天。多因素分析显示肺纤维化评分≥3分(HR 2.16)和肺部照射(HR 3.82)是≥3级急性加重或急性肺损伤/放射性肺炎的显著危险因素。肺纤维化评分≥3分且接受肺部照射者100天累积发生率为37.5%,且全部为5级。

要点

  • 肺纤维化评分≥3分(HR 2.16)和肺部照射(HR 3.82)是≥3级AE-ALI/RP的显著危险因素。
  • 肺纤维化评分≥3分且接受肺部照射者100天累积发生率为37.5%,全部为5级。
  • 肺纤维化评分≥3分未接受肺部照射者100天累积发生率为4.8%。

核心结论

  • 高肺纤维化评分和肺部照射是≥3级AE-ALI/RP的显著危险因素。
  • 即使剂量相对较低,当肺纤维化评分高时,姑息性肺部照射带来极高的AE-ALI/RP风险。

研究设计与样本

  • 回顾性分析2011年1月至2022年1月期间接受姑息性放疗的间质性肺疾病患者数据,共103例。
  • 中位影像随访时间为88天(范围2-1440天),中位生存随访时间为144天(范围8-1441天)。
  • 采用单因素和多因素分析评估与≥3级AE-ALI/RP相关的因素。

主要发现

  • ≥3级AE-ALI/RP的中位发生时间为72天(范围5-206天)。
  • 多因素分析中,肺纤维化评分≥3分与≥3级AE-ALI/RP显著相关(HR 2.16,95%CI 1.36-3.43,p<0.01)。
  • 多因素分析中,肺部照射与≥3级AE-ALI/RP显著相关(HR 3.82,95%CI 1.01-15.73,p=0.04)。
  • 接受肺部照射的患者中,100天生存率为56.8%,≥3级AE-ALI/RP的100天累积发生率为13.7%。
  • 肺纤维化评分≥3分且接受肺部照射的患者中,≥3级AE-ALI/RP的100天累积发生率为37.5%,所有发生≥3级AE-ALI/RP的患者均为5级。

关键数值与推荐

  • 肺纤维化评分≥3分:≥3级AE-ALI/RP的HR为2.16(95%CI 1.36-3.43,p<0.01)。
  • 肺部照射:≥3级AE-ALI/RP的HR为3.82(95%CI 1.01-15.73,p=0.04)。
  • 肺纤维化评分≥3分且接受肺部照射者100天累积发生率为37.5%,肺纤维化评分≥3分未接受肺部照射者为4.8%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Acute exacerbations or acute lung injury, including radiation pneumonitis (AE-ALI/RP) of interstitial lung disease (ILD), has a fatal prognosis. We evaluated the risk of palliative-intent radiotherapy (RT), with or without lung irradiation, for AE-ALI/RP of ILD. MATERIALS AND METHODS: The data of patients with ILD who received palliative-intent RT between January 2011 and January 2022 were retrospectively reviewed. Factors associated with AE-ALI/RP grade ≥ 3 were assessed using univariate and multivariate analyses. RESULTS: One hundred and three patients were examined, with median imaging and survival follow-up times of 88 (2-1440) and 144 (8-1441) days. The median time to onset of AE-ALI/RP grade ≥ 3 was 72 (5-206) days. In multivariate analysis, a higher pulmonary fibrosis score (PFS ≥ 3) (hazard ratio, HR: 2.16; 95% confidence interval, CI: 1.36-3.43; p < 0.01) and lung irradiation (lung-RT) (HR: 3.82; 95% CI: 1.01-15.73; p = 0.04) were significant factors for AE-ALI/RP grade ≥ 3. In patients who received lung-RT, the 100-day survival rate and cumulative incidence of AE-ALI/RP grade ≥ 3 were 56.8% and 13.7%, respectively. In patients with PFS ≥ 3 and who underwent lung-RT, the 100-day cumulative incidence of AE-ALI/RP grade ≥ 3 was 37.5%; all patients with AE-ALI/RP grade ≥ 3 had grade 5. In patients with PFS ≥ 3 without lung-RT, the 100-day cumulative incidence of AE-ALI/RP grade ≥ 3 was 4.8%. CONCLUSION: High PFS and lung-RT are significant risk factors for AE-ALI/RP grade ≥ 3. Even with relatively low doses, palliative-intent lung-RT carries an extremely high risk of AE-ALI/RP when PFS is high.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Makita K, Hamamoto Y, Kanzaki H, et al. Impact of palliative radiotherapy with or without lung irradiation in patients with interstitial lung disease. Radiother Oncol. 2023. PMID: 36963439. doi:10.1016/j.radonc.2023.109636

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。